reference/8916664

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8916664

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Multicenter Study\|Research Support, Non-U.S. Gov't
endingPage	1806
issn	1528-0020 0006-4971
issueIdentifier	12
pageRange	1794-1806
publicationName	Blood
startingPage	1794
bibliographicCitation	Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022 Mar 24;139(12):1794–806. PMID: 34699592; PMCID: PMC10652916.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0c95290656a1cf17d10c9492c04e2453 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4264-8927 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-8772-5028 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-0863-8573 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c75b06bf81f17b4f25f63eca556b1cf7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_df19071b23102355a6c78569bbe182f1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-5292-8298 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_95672cb6f2c8259fe3a40b64bba09b7d http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-2719-0580 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f749cfdca0d90dd1b6d4e4932dc98ecc http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3062-6819 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_06a77a540571be84a1b339b869de430f http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-9188-5008
date	2022-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC10652916 https://pubmed.ncbi.nlm.nih.gov/34699592 https://doi.org/10.1182/blood.2021011895
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1243 https://portal.issn.org/resource/ISSN/0006-4971 https://portal.issn.org/resource/ISSN/1528-0020
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
discusses	http://id.nlm.nih.gov/mesh/M0028310
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D016393Q000209 http://id.nlm.nih.gov/mesh/D015451Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D012008 http://id.nlm.nih.gov/mesh/D000080424 http://id.nlm.nih.gov/mesh/D016219Q000379 http://id.nlm.nih.gov/mesh/D018941 http://id.nlm.nih.gov/mesh/D016219Q000009
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_cad3e44417952acfdf6dd6b23c04a3f7 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID49846579 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24821094 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6700 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_ef3376902b05bdf1d4f2870c2035036b http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10251 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9720 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c47e70e19ed2070e242f94058d118718 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_564f64348efdade903a3b83a985759d0 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_52a517e173e6fa70285ded085be0d86f http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e2e9c6d37ebae8d49121718f1271bff2

Total number of triples: 53.